2024
Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery
Nogueira L, Boffa D, Jemal A, Han X, Yabroff K. Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery. JAMA Network Open 2024, 7: e2351529. PMID: 38214932, PMCID: PMC10787311, DOI: 10.1001/jamanetworkopen.2023.51529.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansInsurance CoverageLung NeoplasmsMaleMedicaidMiddle AgedPatient Protection and Affordable Care ActUnited StatesConceptsMedicaid expansion statusNon-small cell lung cancerMedicaid expansion statesMedicaid expansionSurgical resection of non-small cell lung cancerResection of non-small cell lung cancerDifference-in-differencesExpansion statesPatients' state of residenceNonexpansion statesCohort studyAssociation of Medicaid expansionExpansion statusPostoperative mortalityDifference-in-differences analysisStudy population characteristicsState of residenceAffordable Care ActHealth insurance coverageCohort study of patientsSurgical resectionEarly mortalityMain OutcomesAssociated with declinesCancer outcomes
2023
Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchMeSH KeywordsBronchiCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsPneumonectomyRetrospective StudiesConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingAssociation of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival
Zhang D, Xi Y, Boffa D, Liu Y, Nogueira L. Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival. JAMA Oncology 2023, 9: 1214-1220. PMID: 37498574, PMCID: PMC10375383, DOI: 10.1001/jamaoncol.2023.2144.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChildCohort StudiesFemaleHumansLung NeoplasmsMaleNeoplasm StagingWildfiresConceptsNon-small cell lung cancerOverall survivalWorse overall survivalLung cancerNSCLC surgeryCohort studyHazard ratioSurgical resectionNSCLC resectionLong-term overall survivalNational Cancer DatabaseLung cancer surgeryLymph node involvementCell lung cancerHealth insurance typeHealth hazardsHospital dischargeNode involvementCancer surgeryStudy endTumor sizeCancer DatabaseInsurance typeHigh riskUnexposed individuals
2022
Thoracic CT follow-up after non-small-cell lung cancer resection
Woodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.Commentaries, Editorials and LettersCarcinoma, Non-Small-Cell LungFollow-Up StudiesHumansLung NeoplasmsPneumonectomyRetrospective StudiesTomography, X-Ray ComputedImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansImmunotherapyLung NeoplasmsMaleNeoplasm StagingConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useAssociation of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer
Udelsman BV, Chang DC, Boffa DJ, Gaissert HA. Association of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2022, 115: 166-173. PMID: 35752354, DOI: 10.1016/j.athoracsur.2022.05.051.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsLymph Node ExcisionLymph NodesNeoplasm StagingPneumonectomyRetrospective StudiesThoracic Surgery, Video-AssistedConceptsNon-small cell lung cancerHigh-volume centersThoracic Surgeons General Thoracic Surgery DatabaseGeneral Thoracic Surgery DatabaseMedium-volume centersLow-volume centersCell lung cancerThoracic Surgery DatabaseNodal harvestParticipant centersLymph nodesLung cancerSurgery DatabaseLymph node samplingMultivariable logistic regressionHigher center volumeLong-term survivalPotential quality metricElective lobectomyAdjuvant therapyNodal yieldGuideline adherencePrimary outcomeUnivariable analysisMultivariable analysisAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellCohort StudiesHumansImmunotherapyKidney NeoplasmsLung NeoplasmsMaleMelanomaUnited StatesUnited States Food and Drug AdministrationConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristics
2021
Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer
Woodard GA, Li A, Boffa DJ. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2021, 163: 1685-1692. PMID: 34334172, DOI: 10.1016/j.jtcvs.2021.05.053.Peer-Reviewed Original ResearchCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyHumansLung NeoplasmsNeoplasm StagingAdjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules
Li AX, Flores K, Canavan ME, Boffa DJ, Blasberg JD. Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. The Annals Of Thoracic Surgery 2021, 113: 421-428. PMID: 33684345, DOI: 10.1016/j.athoracsur.2021.02.042.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDifferent ipsilateral lobeCell lung cancerAdditional tumor nodulesT4 non-small cell lung cancerAdjuvant chemotherapyIpsilateral lobeT4 diseaseTumor nodulesLung cancerT4 tumorsOverall survivalSurgical resectionIIIA non-small cell lung cancerAdjuvant multiagent chemotherapyResectable stage IINational Cancer DatabaseFurther prospective studiesLymph node metastasisMultiagent chemotherapyNode metastasisPrimary outcomeProspective studyPatient populationCancer DatabaseAdjuvant Chemotherapy in Patients With Early-Stage Non–Small Cell Lung Cancer—Reply
Pathak R, Boffa DJ. Adjuvant Chemotherapy in Patients With Early-Stage Non–Small Cell Lung Cancer—Reply. JAMA Oncology 2021, 7: 638-638. PMID: 33630034, DOI: 10.1001/jamaoncol.2020.8194.Peer-Reviewed Original Research
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCohort StudiesFemaleHumansLung NeoplasmsNeoplasm StagingRetrospective StudiesConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patientsAssociation of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedRetrospective StudiesConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerFirst-line ICI treatmentImmune checkpoint inhibitorsPD-L1 expressionPD-L1 testingNegative PD-L1 expressionHigh PD-L1 expressionCell lung cancerICI treatmentCheckpoint inhibitorsLung cancerDeath ligand 1 (PD-L1) expression statusElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsCell death ligand 1 (PD-L1) expressionExpression statusLow PD-L1 expressionPD-L1 expression statusDeath ligand 1 (PD-L1) expressionRetrospective cohort studyFirst-line treatmentLigand 1 expressionProportion of patientsReal-world careCommentary: The majority of minorities
Salazar MC, Boffa DJ. Commentary: The majority of minorities. Journal Of Thoracic And Cardiovascular Surgery 2020, 160: 272-273. PMID: 32033814, DOI: 10.1016/j.jtcvs.2019.12.067.Peer-Reviewed Original Research
2019
Commentary: How surprising
Boffa DJ, Salazar M. Commentary: How surprising. Journal Of Thoracic And Cardiovascular Surgery 2019, 159: 2483-2484. PMID: 32033820, DOI: 10.1016/j.jtcvs.2019.11.118.Peer-Reviewed Original ResearchComparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV disease
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvival
2016
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2016, 103: 75-81. PMID: 28024700, DOI: 10.1016/j.lungcan.2016.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDatabases, FactualFemaleGuidelines as TopicHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePneumonectomyPostoperative PeriodRadiotherapySmall Cell Lung CarcinomaSurvival AnalysisConceptsStage I small cell lung cancerClinical stage ISmall cell lung cancerCell lung cancerAdjuvant chemotherapySurgical resectionPathologic upstagingStage IRadiation therapyNodal diseaseLung cancerPositive lymph node involvementNational Cancer DatabaseOutcomes of patientsLymph node involvementProportion of patientsCurative intentNodal upstagingSCLC patientsUpstaged patientsAdjuvant therapyNode involvementIndependent predictorsInferior survivalT descriptorRole of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumors